Literature DB >> 33006613

Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry.

Marco Proietti1,2,3, Gregory Y H Lip3,4, Cécile Laroche5, Laurent Fauchier6, Francisco Marin7, Michael Nabauer8, Tatjana Potpara9,10, Gheorghe-Andrei Dan11, Zbigniew Kalarus12, Luigi Tavazzi13, Aldo Pietro Maggioni5,13, Giuseppe Boriani14.   

Abstract

AIMS: There has been an increasing focus on integrated, multidisciplinary, and holistic care in the treatment of atrial fibrillation (AF). The 'Atrial Fibrillation Better Care' (ABC) pathway has been proposed to streamline integrated care in AF. We evaluated the impact on outcomes of an ABC adherent management in a contemporary real-life European-wide AF cohort. METHODS AND
RESULTS: Patients enrolled in the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry with baseline data to evaluate ABC criteria and available follow-up data were considered for this analysis. Among the original 11 096 AF patients enrolled, 6646 (59.9%) were included in this analysis, of which 1996 (30.0%) managed as ABC adherent. Patients adherent to ABC care had lower CHA2DS2-VASc and HAS-BLED scores (mean ± SD, 2.68 ± 1.57 vs. 3.07 ± 1.90 and 1.26 ± 0.93 vs. 1.58 ± 1.12, respectively; P < 0.001). At 1-year follow-up, patients managed adherent to ABC pathway compared to non-adherent ones had a lower rate of any thromboembolic event (TE)/acute coronary syndrome (ACS)/cardiovascular (CV) death (3.8% vs. 7.6%), CV death (1.9% vs. 4.8%), and all-cause death (3.0% vs. 6.4%) (all P < 0.0001). On Cox multivariable regression analysis, ABC adherent care showed an association with a lower risk of any TE/ACS/CV death [hazard ratio (HR): 0.59, 95% confidence interval (CI): 0.44-0.79], CV death (HR: 0.52, 95% CI: 0.35-0.78), and all-cause death (HR: 0.57, 95% CI: 0.43-0.78).
CONCLUSION: In a large contemporary cohort of European AF patients, a clinical management adherent to ABC pathway for integrated care is associated with a significant lower risk for cardiovascular events, CV death, and all-cause death. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Integrated care; Outcomes • Registry

Year:  2021        PMID: 33006613     DOI: 10.1093/europace/euaa274

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  13 in total

1.  Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry.

Authors:  María Asunción Esteve-Pastor; Martín Ruiz-Ortiz; Javier Muñiz; Inmaculada Roldán-Rabadán; Déborah Otero; Ángel Cequier; Vicente Bertomeu-Martínez; Lina Badimón; Manuel Anguita; Gregory Y H Lip; Francisco Marín
Journal:  Front Cardiovasc Med       Date:  2022-05-02

2.  Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Authors:  Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara
Journal:  Intern Emerg Med       Date:  2021-12-02       Impact factor: 5.472

3.  Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation.

Authors:  Giuseppe Boriani; Saverio Iacopino; Giuseppe Arena; Paolo Pieragnoli; Roberto Verlato; Massimiliano Manfrin; Giulio Molon; Giovanni Rovaris; Antonio Curnis; Giovanni Battista Perego; Antonio Dello Russo; Maurizio Landolina; Marco Vitolo; Claudio Tondo
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-21

4.  Atrial fibrillation.

Authors: 
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 65.038

Review 5.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

6.  The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.

Authors:  Yuan Yao; Yutao Guo; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2021-12-01

7.  Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry.

Authors:  Giuseppe Boriani; Gregory Y H Lip; Marco Proietti; Marco Vitolo; Stephanie L Harrison; Deirdre A Lane; Laurent Fauchier; Francisco Marin; Michael Nabauer; Tatjana S Potpara; Gheorghe-Andrei Dan
Journal:  Clin Res Cardiol       Date:  2021-08-27       Impact factor: 5.460

8.  Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry.

Authors:  Agnieszka Kotalczyk; Yutao Guo; Maria Stefil; Yutang Wang; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2022-04-04       Impact factor: 6.106

Review 9.  Imaging Techniques for the Study of Fibrosis in Atrial Fibrillation Ablation: From Molecular Mechanisms to Therapeutical Perspectives.

Authors:  Francesco De Sensi; Diego Penela; David Soto-Iglesias; Antonio Berruezo; Ugo Limbruno
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

10.  Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists.

Authors:  Vanessa Roldán; Lorena Martínez-Montesinos; Raquel López-Gálvez; Lucía García-Tomás; Gregory Y H Lip; José Miguel Rivera-Caravaca; Francisco Marín
Journal:  J Pers Med       Date:  2022-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.